COMMUNIQUÉS West-GlobeNewswire

Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections
21/10/2025
TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, [...]
Lighthouse Autism Center Appoints Joseph Giles as Chief Executive Officer and Chair of the Board
21/10/2025
MISHAWAKA, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Lighthouse Autism Center (“Lighthouse” or the “Company”), a premier provider of center-based Applied Behavior Analysis (“ABA”) therapy, is pleased to announce the [...]
CorVel Corporation to Host Live Earnings Release Webcast
21/10/2025
FORT WORTH, Texas, Oct. 21, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its [...]
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
21/10/2025
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
21/10/2025
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies First patient dosing planned before year-end 2025 at leading cancer [...]
WORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience
21/10/2025
Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
Armada and Eclipse Energy Partner to Accelerate Commercialization of Critical Edge Technologies for Global Industrial Challenges
21/10/2025
SAN FRANCISCO and HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Armada and Eclipse Energy (formerly Gold H2) today announced a strategic partnership to accelerate the commercialization and reliability of critical edge [...]
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
21/10/2025
Three Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with Consistent Cognitive and Neuroimaging Benefits [...]
Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
21/10/2025
The 2026 Award is focused on research in paediatric oncology, specifically sarcomas Paediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little innovation in treatment [...]
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
21/10/2025
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
21/10/2025
Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk. “ [...]
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
21/10/2025
79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer [...]
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
21/10/2025
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER [...]
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
21/10/2025
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: [...]
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
21/10/2025
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
21/10/2025
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation [...]
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
21/10/2025
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
21/10/2025
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral session SHANGHAI and WALTHAM, Mass., [...]
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
21/10/2025
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a [...]

Pages